Detect early loss of dopamine
- Trial ID
- NCT06456684
- Official Title
- AV133 Longitudinal Imaging Study in Patients With Early and Prodromal Parkinson's Disease
- Goal
- Detect early loss of dopamine
- Status
- RECRUITING
- Sponsor
- Xuanwu Hospital, Beijing
- Study Type
- OBSERVATIONAL
- Enrollment
- 76 participants
- Conditions
- Parkinson Disease
- Interventions
- Fluoro[18F]promethazine
Plain-Language Summary
Goal: find and track early loss of dopamine nerve terminals in people with very early or prodromal Parkinson's by detecting reductions in VMAT2, a protein that reflects how healthy dopamine storage in nerve endings is. Approach: participants undergo AV133 PET scans using Fluoro[18F]promethazine, a radioactive tracer that binds VMAT2 so clinicians can visualize and quantify dopamine terminal loss over time; this is an imaging test not a treatment, and people already on levodopa or other Parkinson medications are excluded because those drugs can alter the PET signal. Eligibility: looking for adults 30 and older with a clinical Parkinson's diagnosis within two years and Hoehn and Yahr stage I or II who show AV133 changes, plus a prodromal group generally 60 and older or 30 and older if they have certain genetic risks; everyone must be able to consent and not yet started on PD medications, and some stimulants or interfering drugs must be stopped before imaging.
Locations
- Xuan Wu Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Fluoro[18F]promethazine. Goal: find and track early loss of dopamine nerve terminals in people with very early or prodromal Parkinson's by detecting reductions in VMAT2, a protein that reflects how healthy dopamine storage in nerve endings is. Approach: participants undergo AV133 PET scans using Fluoro[18F]promethazine, a radioactive tracer that binds VMAT2 so clinicians can visualize and quantify dopamine terminal loss over time; this is an imaging test not a treatment, and people already on levodopa or other Parkinson medications are excluded because those drugs can alter the PET signal. Eligibility: looking for adults 30 and older with a clinical Parkinson's diagnosis within two years and Hoehn and Yahr stage I or II who show AV133 changes, plus a prodromal group generally 60 and older or 30 and older if they have certain genetic risks; everyone must be able to consent and not yet started on PD medications, and some stimulants or interfering drugs must be stopped before imaging.
- Who can participate?
- Participants must be at least 30 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 2 years and 6 months.